Immunome, Inc.
Immunome is a clinical-stage oncology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. With a team experienced in the design, development, and commercialization of cutting-edge treatments, including antibody-drug conjugates (ADCs), the company aims to improve outcomes for cancer patients by advancing a diverse portfolio of innovative therapeutic candidates.
Industries
Nr. of Employees
small (1-50)
Immunome, Inc.
18702 North Creek Parkway, Suite 100, Bothell, WA 98011
Patents
Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating Adenoid Cystic Carcinoma
US-12233072-B2
View Details
Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating Adenoid Cystic Carcinoma
US-12233072-B2
View DetailsProducts
Gamma-secretase inhibitor (clinical-stage)
Small-molecule gamma-secretase inhibitor in late-stage clinical development for treatment of desmoid tumors.
ROR1-targeted antibody-drug conjugate (early clinical)
A ROR1-directed antibody-drug conjugate advancing in early-phase clinical testing for solid tumors.
FAP-targeted radioligand therapy (IND-stage)
Radioligand therapy directed at fibroblast activation protein (FAP) that has progressed to IND submission/clearance.
Preclinical ADC candidates (undisclosed targets)
Multiple preclinical antibody-drug conjugate candidates developed against targets with expression in solid tumors, intended for pipeline expansion.
Gamma-secretase inhibitor (clinical-stage)
Small-molecule gamma-secretase inhibitor in late-stage clinical development for treatment of desmoid tumors.
ROR1-targeted antibody-drug conjugate (early clinical)
A ROR1-directed antibody-drug conjugate advancing in early-phase clinical testing for solid tumors.
FAP-targeted radioligand therapy (IND-stage)
Radioligand therapy directed at fibroblast activation protein (FAP) that has progressed to IND submission/clearance.
Preclinical ADC candidates (undisclosed targets)
Multiple preclinical antibody-drug conjugate candidates developed against targets with expression in solid tumors, intended for pipeline expansion.
Services
Design and execution of oncology clinical trials including early- and late-stage studies and regulatory interactions to advance candidates.
Process development, manufacturing optimization, and analytical development to support biologics and drug-linker product advancement and scale-up.
Business development capabilities to identify, acquire, and integrate targeted oncology assets and to structure partnering opportunities.
Design and execution of oncology clinical trials including early- and late-stage studies and regulatory interactions to advance candidates.
Process development, manufacturing optimization, and analytical development to support biologics and drug-linker product advancement and scale-up.
Business development capabilities to identify, acquire, and integrate targeted oncology assets and to structure partnering opportunities.
Expertise Areas
- Clinical trial management
- Antibody-drug conjugate development
- Radioligand therapy development
- Small-molecule oncology development
Key Technologies
- Antibody-drug conjugates (ADC) platform
- Radioligand therapy (RLT)
- Small-molecule inhibitor development
- Linker-payload chemistry